Alerts will be sent to your verified email
Verify Email
WINDLAS
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Windlas Biotech Limited is a leading pharmaceutical CDMO company in India, offering a wide range of development and manufacturing services of high-quality and cost-effective products globally, along with branded products in trade generics and OTC markets.
Windlas Biotech major competitors are SMS Pharmaceuticals, Amrutanjan Healthcar, Beta Drugs, Morepen Laboratories, Panacea Biotec, Bliss GVS Pharma, Indoco Remedies.
Market Cap of Windlas Biotech is ₹2,193 Crs.
While the median market cap of its peers are ₹2,080 Crs.
Windlas Biotech seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | May Aug | Mar Jun Sep Dec | Sep Dec | |||||||||||||||
| Investor Presentation | May Aug | Mar Jun Sep Dec | Feb Mar May Jun Sep Dec | Feb Mar May Jun Aug Sep Nov | Jun Sep Dec | |||||||||||||
| Conference Call | Mar | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep | Sep Dec | |||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
